TY - JOUR T1 - Benefits of Enhancing the Platinum-Free Interval in the Treatment of Relapsed Ovarian Cancer: More Than Just a Hypothesis? JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - S9 LP - S11 DO - 10.1097/IGC.0b013e318217b30b VL - 21 IS - Supp 1 AU - Jonathan A. Ledermann Y1 - 2011/05/01 UR - http://ijgc.bmj.com/content/21/Supp_1/S9.abstract N2 - There is some evidence from in vitro studies as well as case series that patients with documented platinum resistance will respond to platinum after a nonplatinum drug. In addition, retrospective case studies have demonstrated the difficulty in determining if delaying second platinum is detrimental or beneficial. For that reason, a prospective Italian randomized trial conducted by the Multicenter Italian Trials in Ovarian Cancer (MITO) Group (MITO-8), comparing nonplatinum with platinum-based therapy is being performed to assess the effects of delaying platinum on survival. ER -